...
首页> 外文期刊>Cytometry, Part B. Clinical cytometry: the journal of the International Society for Analytical Cytology >Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - Part IV - Postanalytic considerations
【24h】

Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - Part IV - Postanalytic considerations

机译:基于细胞的荧光测定法的验证:ICSH和ICCS的操作准则-第四部分-分析后的注意事项

获取原文
获取原文并翻译 | 示例
           

摘要

Flow cytometry and other technologies of cell-based fluorescence assays are as a matter of good laboratory practice required to validate all assays, which when in clinical practice may pass through regulatory review processes using criteria often defined with a soluble analyte in plasma or serum samples in mind. Recently the U.S. Food and Drug Administration (FDA) has entered into a public dialogue in the U.S. regarding their regulatory interest in laboratory developed tests (LDTs) or so-called home brew assays performed in clinical laboratories. The absence of well-defined guidelines for validation of cell-based assays using fluorescence detection has thus become a subject of concern for the International Council for Standardization of Haematology (ICSH) and International Clinical Cytometry Society (ICCS). Accordingly, a group of over 40 international experts in the areas of test development, test validation, and clinical practice of a variety of assay types using flow cytometry and/or morphologic image analysis were invited to develop a set of practical guidelines useful to in vitro diagnostic (IVD) innovators, clinical laboratories, regulatory scientists, and laboratory inspectors. The focus of the group was restricted to fluorescence reporter reagents, although some common principles are shared by immunohistochemistry or immunocytochemistry techniques and noted where appropriate. The work product of this two year effort is the content of this special issue of this journal, which is published as 5 separate articles, this being Validation of Cell-based Fluorescence Assays: Practice Guidelines from the ICSH and ICCS - Part IV - Postanalytic considerations.
机译:流式细胞仪和其他基于细胞的荧光测定技术属于验证所有测定所需的良好实验室操作规范,在临床实践中,使用通常以血浆或血清样品中可溶性分析物定义的标准进行临床检查时,可能会通过监管审查程序心神。最近,美国食品药品监督管理局(FDA)已就其对实验室开发的测试(LDT)或在临床实验室中进行的所谓家庭酿造分析的监管兴趣在美国进行了公开对话。因此,对于使用荧光检测验证基于细胞的测定方法缺乏明确的指导原则,这已成为国际血液学标准化理事会(ICSH)和国际临床细胞计数学会(ICCS)的关注主题。因此,邀请了40多位国际专家组成的小组,涉及使用流式细胞仪和/或形态学图像分析进行各种分析类型的测试开发,测试验证和临床实践领域,以开发一套可用于体外的实用指南。诊断(IVD)创新者,临床实验室,监管科学家和实验室检查员。尽管免疫组织化学或免疫细胞化学技术共有一些共同的原理,并在适当的地方加以注意,但该小组的焦点仅限于荧光报告试剂。两年努力的成果是本期刊的特刊,该刊物分5篇发表,这是《基于细胞的荧光测定法的验证:来自ICSH和ICCS的实践指南-第四部分-分析后的注意事项。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号